Jan 24, 2020 - With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Jan 24, 2020 - Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Jan 24, 2020 - J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Jan 22, 2020 - Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Jan 22, 2020 - Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Jan 21, 2020 - Chinese drugmaker BeiGene would compete directly with Merck's cancer superdrug.
Jan 21, 2020 - The blockbuster drug is already approved for three other types of tumors.
Jan 20, 2020 - Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.
Jan 17, 2020 - J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.